U.S. markets closed

Evoke Pharma, Inc. (EVOK)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.6500+0.1100 (+7.14%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.5400
Open1.5600
Bid1.6500 x 3200
Ask1.7000 x 2200
Day's Range1.5400 - 1.6800
52 Week Range1.1000 - 6.0630
Volume518,950
Avg. Volume751,719
Market Cap53.414M
Beta (5Y Monthly)1.12
PE Ratio (TTM)N/A
EPS (TTM)-0.5160
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®
    GlobeNewswire

    Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®

    New patent expands intellectual property protection for nasal delivery of metoclopramideSOLANA BEACH, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance to Evoke for U.S. Application No. 16/181,841 for Gimoti® (metoclopramide) nasal spray. When granted, the patent will cover methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis. The patent, entitled “Nasal Formulations of Metoclopramide,” carries a patent term to at least 2029. Gimoti is Evoke’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis. The U.S. Food and Drug Administration (FDA) approved the New Drug Application for Gimoti in June 2020. This new patent covers Gimoti for gastroparesis and will be listable in FDA’s Orange Book. “We are pleased with this additional USPTO determination that Gimoti is innovative and novel. We believe Gimoti provides an important option for treating diabetic gastroparesis patients with nasal delivery, especially as the disease can cause patients to experience delayed digestion of oral medications,” commented Dave Gonyer, President and CEO. “The issuance of this Notice of Allowance strengthens the intellectual property protection for Gimoti and will provide another Orange Book-listable patent and a significant addition to our intellectual property estate and overall marketing strategy for Gimoti.” About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Safe Harbor Statement Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on Evoke’s current beliefs and expectations. These forward-looking statements include statements regarding Evoke’s expectations on the scope of any patent protection. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties associated Evoke’s ability to obtain and maintain intellectual property protection for GIMOTI and other risks and uncertainties inherent in Evoke’s business, including those described in Evoke’s periodic filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contacts:The Ruth GroupChristine Petraglia / James SaliernoTel: 917-633-8980 / 973-255-8361cpetraglia@theruthgroup.com / jsalierno@theruthgroup.com Media Contact:The Ruth GroupAnnika ParrishTel: 720-412-9042aparrish@theruthgroup.com

  • Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
    GlobeNewswire

    Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis

    SOLANA BEACH, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will host a fireside chat on Thursday, April 1, 2021, at 1:00pm ET with Dr. Kostas Sideridis, DO, an early adopter of GIMOTI and co-founder of Long Island Gastro, and Dr. Richard McCallum, MD, Division of Gastroenterology, Center for Neurogastroenterology and GI Motility, Texas Tech University Health Sciences Center El Paso. Details of the fireside chat are below:Date:Thursday, April 1, 2021Location:https://edge.media-server.com/mmc/p/hszv2spzTime:1:00pm ET In addition, investors are encouraged to email syndicate@laidlawltd.com prior to the event with questions they may have for Dr. Sideridis and Dr. McCallum. During the call, Laidlaw & Company may be asking several submitted questions to Dr. Sideridis and Dr. McCallum. About Evoke Pharma, Inc. Evoke is a specialty pharmaceutical company focused primarily on the commercialization and development of drugs to treat GI disorders and diseases. The Company developed GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis. Investor Contacts:The Ruth GroupChristine Petraglia / James SaliernoTel: 917-633-8980 / 973-255-8361cpetraglia@theruthgroup.com / jsalierno@theruthgroup.com Media Contact:The Ruth GroupAnnika ParrishTel: 720-412-9042aparrish@theruthgroup.com

  • Evoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near Future
    Simply Wall St.

    Evoke Pharma, Inc. (NASDAQ:EVOK) Is Expected To Breakeven In The Near Future

    We feel now is a pretty good time to analyse Evoke Pharma, Inc.'s ( NASDAQ:EVOK ) business as it appears the company...